sellWeak
Astrid Borkowski sold $155k of HLVX
Chief Medical Officer at HilleVax, Inc.. 10,000 shares at an average of $15.50, traded Dec 15, 2023, filed Dec 18, 2023.
Warning score
26Value
$155k
10,000 shares
Holdings after
165,193
-6% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +11Trade size$155k at market
- 0Share of holdings soldSold 5.7% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-071185, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2023 | SOpen-market sale Common Stock | -10,000 | $15.50 | $155k | 165,193 | Dec 18, 2023 |
Related signals
Other insiders at HilleVax, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | HilleVax, Inc. | Robert Hershberg See Remarks | $49k 26,535 shares | -2% | |
| 30Weak | HilleVax, Inc. | Shane Maltbie Chief Financial Officer | $15k 8,291 shares | -9% | |
| 20Weak | HilleVax, Inc. | Aditya Kohli director | $986M 18,000 shares | -2% | |
| 10Weak | HilleVax, Inc. | Aditya Kohli director | $336k 18,000 shares | -2% | |
| 23Weak | HilleVax, Inc. | Aditya Kohli director | $269k 18,000 shares | -2% | |
| 19Weak | HilleVax, Inc. | Aditya Kohli director | $92k 6,000 shares | -1% | |
| 37Weak | HilleVax, Inc. | Astrid Borkowski Chief Medical Officer | $59k 3,933 shares | -2% | |
| 41Moderate | HilleVax, Inc. | Robert Hershberg See Remarks | $173k 11,597 shares | -1% | |
| 44Moderate | HilleVax, Inc. | Shane Maltbie Chief Financial Officer | $53k 3,576 shares | -8% | |
| 41Moderate | HilleVax, Inc. | Aditya Kohli director | $132k 8,866 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.